Aberdeen Group plc and abrdn Inc. Report 8.6% Ownership in IMMUNIC, INC

SEC Filing SCHEDULE 13G (0001085146-25-004384)

Aberdeen Group plc and abrdn Inc. have filed a Schedule 13G with the SEC, reporting an 8.6% ownership in IMMUNIC, INC. The filing indicates that Aberdeen Group plc and abrdn Inc. beneficially own 8,243,941 shares of IMMUNIC's common stock. Aberdeen Group plc is the parent company, while abrdn Holdings Limited is the intermediate holding company for abrdn Inc. The shares are held on behalf of underlying clients, and the filing certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing the control of the issuer. The filing was made under Rule 13d-1(b).